<DOC>
	<DOC>NCT02827578</DOC>
	<brief_summary>Efficacy and Safety of Tamsulosin/Solifenacin Combination therapy in Patients with voiding symptoms and moderate to severe storage symptoms due to Benign Prostate Hyperplasia : a randomized, double blinded, parallel design, active controlled, multi-center, phase 3 clinical trial</brief_summary>
	<brief_title>Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>1. Healthy male aged 45 years old or older 2. Subjects with benign prostatic hyperplasia diagnosed by digital rectal examination 3. Subjects with lower urinary tract symptom suggestive of benign prostate hyperplasia, who spontaneously agree to join and sign to the consent form 1. Subjects who have a history of the lower urinary tract cancer, including prostate cancer and bladder cancer within the past 5 years 2. Subjects who have acute urinary retention within 4 weeks before screening 3. Subjects who have clinically significant severe cardiovascular disease(unstable angina, myocardial infarction or arrhythmia) within 6 months before screening 4. Subjects who have hypersensitivity to investigational product or sulfa medications 5. Subjects who were suspected or confirmed calculus of lower urinary tract, calculus of bladder (except for complete recovery,) 6. Subjects who have myasthenia gravis, narrow angle glaucoma or autonomic neuropathy 7. Subjects who have cataract or glaucoma scheduled to be operated in the study duration. 8. Subjects who have hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption 9. Subjects who are judged by the investigators to be unsuitable to participate in the clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>